Inhibition of Proliferation and Induction of Apoptosis in Multiple Myeloma Cell Lines by CD137 Ligand Signaling by Gullo, Charles A., PhD et al.
Marshall University
Marshall Digital Scholar
Biochemistry and Microbiology Faculty Research
Spring 5-26-2010
Inhibition of Proliferation and Induction of
Apoptosis in Multiple Myeloma Cell Lines by
CD137 Ligand Signaling
Charles A. Gullo PhD
Marshall Univeristy, gullo@marshall.edu
Liang Kai Koh
Wan Lu Pang
Kian Tong Ho
Shi Hao Tan
See next page for additional authors
Follow this and additional works at: http://mds.marshall.edu/sm_bm
Part of the Medical Cell Biology Commons, and the Medical Specialties Commons
This Article is brought to you for free and open access by the Faculty Research at Marshall Digital Scholar. It has been accepted for inclusion in
Biochemistry and Microbiology by an authorized administrator of Marshall Digital Scholar. For more information, please contact
zhangj@marshall.edu.
Recommended Citation
Gullo C, Koh LK, Pang WL, Ho KT, Tan SH, Schwarz H (2010) Inhibition of Proliferation and Induction of Apoptosis in Multiple
Myeloma Cell Lines by CD137 Ligand Signaling. PLoS ONE 5(5): e10845. doi:10.1371/journal.pone.0010845
Authors
Charles A. Gullo PhD, Liang Kai Koh, Wan Lu Pang, Kian Tong Ho, Shi Hao Tan, and Herbert Schwarz
This article is available at Marshall Digital Scholar: http://mds.marshall.edu/sm_bm/142
Inhibition of Proliferation and Induction of Apoptosis in
Multiple Myeloma Cell Lines by CD137 Ligand Signaling
Charles Gullo1, Liang Kai Koh2, Wan Lu Pang2, Kian Tong Ho1, Shi Hao Tan2, Herbert Schwarz2*
1Cancer Immunology Laboratory, Department of Clinical Research, Singapore General Hospital, Singapore, Singapore, 2Department of Physiology, Yong Loo Lin School
of Medicine, National University of Singapore, Singapore, Singapore
Abstract
Background: Multiple myeloma (MM) is a malignancy of terminally-differentiated plasma cells, and the second most
prevalent blood cancer. At present there is no cure for MM, and the average prognosis is only three to five years. Current
treatments such as chemotherapy are able to prolong a patient’s life but rarely prevent relapse of the disease. Even
hematopoietic stem cell transplants and novel drug combinations are often not curative, underscoring the need for a
continued search for novel therapeutics. CD137 and its ligand are members of the Tumor Necrosis Factor (TNF) receptor and
TNF superfamilies, respectively. Since CD137 ligand cross-linking enhances proliferation and survival of healthy B cells we
hypothesized that it would also act as a growth stimulus for B cell cancers.
Methodology/Principal Findings: Proliferation and survival of B cell lymphoma cell lines were not affected or slightly
enhanced by CD137 ligand agonists in vitro. But surprisingly, they had the opposite effects on MM cells, where CD137 ligand
signals inhibited proliferation and induced cell death by apoptosis. Furthermore, secretion of the pro-inflammatory
cytokines, IL-6 and IL-8 were also enhanced in MM but not in non-MM cell lines in response to CD137 ligand agonists. The
secretion of these cytokines in response to CD137 ligand signaling was consistent with the observed activation of the
classical NF-kB pathway. We hypothesize that the induction of this pathway results in activation-induced cell death, and
that this is the underlying mechanism of CD137-induced MM cell death and growth arrest.
Conclusions/Significance: These data point to a hitherto unrecognized role of CD137 and CD137 ligand in MM cell biology.
The selective inhibition of proliferation and induction of cell death in MM cells by CD137 ligand agonists may also warrant a
closer evaluation of their therapeutic potential.
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Introduction
Multiple myeloma (MM) is a malignancy of terminally
differentiated plasma cells that primarily resides at multiple sites
in the bone marrow and is clinically characterized by osteolytic
lesions, immunodeficiency, and renal disease. MM represents 20%
of all new hematological malignancies, making it the second most
prevalent blood cancer [1]. Epidemiologic data indicate both an
increasing incidence and an earlier age of onset of the disease.
Despite currently available chemotherapeutic treatments and
autologous transplantation resulting in an improvement in overall
survival of patients, MM still remains incurable and the average
prognosis is only three years to five years [2].
Stem cell transplantation can provide long-term remission, but
the procedure suffers from a high treatment-related mortality, and
the majority of patients relapse [3]. More recently, agents with
novel mechanisms of action, such as the proteasome inhibitor,
bortezomib and immunomodulatory drugs like thalidomide and
lenalidomide have shown promise for treatment of patients with
refractory and relapsed disease, and for those with previously
untreated multiple myeloma [4,5]. Even with these novel drugs,
the majority of MM patients eventually experience relapse, their
disease becomes chemoresistant, and they die of the disease [6,7].
Therefore, an approach that allows targeting and selective killing
of cancerous MM cells remains highly desirable.
CD137 (TNFRSF9, 4-1BB, ILA) is a cytokine receptor and a
member of the tumor necrosis factor receptor family, and a potent
T cell costimulatory molecule [8–10]. The ligand for CD137 is
expressed by antigen presenting cells (APC) and APC use the
CD137 receptor/ligand system to costimulate T cell activity. APC
express CD137 ligand as a cell surface transmembrane protein,
and CD137 ligand can transduce signals into APC, a process
known as reverse signaling. Therefore, bidirectional signaling exist
for the CD137 receptor/ligand system [11]. CD137 ligand signals
induce activation, survival, proliferation and migration of
monocytes [12–17], maturation of dendritic cells [18,19], and
proliferation and differentiation of hematopoietic progenitor cells
[20,21]. However, the signaling pathways emanating from the
ligand and its physiologic role in immune regulation have only
partly been characterized.
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Previous data highlights the importance of the CD137 ligand
signaling in B cell maturation and activation. In B cells CD137
ligand signaling enhances proliferation and immunoglobulin
synthesis [22]. B cells likely receive signals via CD137 ligand
when interacting with either CD137-expressing helper T cells or
CD137-expressing follicular dendritic cells in germinal centers
[22,23]. It was postulated that similarly to the CD40 receptor/
ligand system, which mediates T cell help to B cells after first
antigen encounter, the CD137 receptor/ligand system may
mediate costimulation of B cells by follicular dendritic cells during
affinity maturation [22].
We hypothesized that the CD137 ligand signal may have similar
activating effects on malignant B cells, and thereby possibly
support B cell cancers. Here we describe that the opposite is true
in MM cells where CD137 ligand signals inhibit proliferation and
induce cell death by apoptosis, while proliferation and survival of
non-MM B cell lymphoma cell lines are not affected. Secretion of
the pro-inflammatory cytokines IL-6 and IL-8 is also increased in
MM cell lines following CD137 ligand activation but not in non-
MM cell lines. CD137 ligand signals also activate the classical NF-
kB pathway in the MM cell lines. This data suggests that
crosslinking of CD137 ligand on MM cell lines might represent a
novel method to specifically target MM cells for destruction. It also
suggests that at least in some B cell cancers, CD137 ligand
induction results in the early activation of the NF-kB pathway that
induces a pro-inflammatory as well as a pro-apoptotic state.
Materials and Methods
Recombinant proteins and antibodies
CD137-Fc protein was purified from supernatants of stably
transfected CHO cells by protein G sepharose, as described
previously [24]. Human IgG1 Fc fragment was purchased from
Chemicon (Temecula, CA, USA). Antibodies used in this study
includes PE-conjugated mouse IgG1, k isotype control (clone
MOPC-21, Sigma-Aldrich, USA), anti-human CD137 (clone 4B4-
1, BD Pharmingen, USA), anti-human 4-1BB ligand (clone 5F4,
Biolegend, USA, and clone 41B436 Alexis Biochemicals, Switzer-
land), unlabelled mouse IgG1, k isotype control (clone MOPC-21,
Sigma, USA).
Cells
RPMI-8226 and Raji were obtained from ATCC (Manassas,
VA, USA). DOHH-2 and SUDHL-4 were obtained from the
Deutsche Sammlung von Mikroorganismen und Zellkulturen
GmbH (DSMZ, Germany). The SGH-MM5 and SHG-MM6
human MM cell lines were developed in our laboratory from a
patient with MM using a modified Dexter-type long-term tissue
culture system, as described previously [25].
Crosslinking of CD137 ligand
CD137 ligand was crosslinked by monoclonal antibodies
specific for CD137 ligand, or by a recombinant fusion protein
consisting of the extracellular domain of CD137 and the constant
domain (Fc) of IgG1 (CD137-Fc). Isotype antibodies or a
recombinant Fc protein were used as negative controls, respec-
tively. These proteins were immobilized onto tissue culture plates
by coating at 4uC overnight, to enable them to crosslink CD137
ligand on the lymphoma and MM cells. Unless otherwise indicated
at 10 mg/ml protein solutions were used.
Flow cytometric analysis
Aliquots of cultured cells (2236105 cells) were stained with
respective fluorochrome conjugated antibodies in PBS containing
0.5% FBS and 0.1% sodium azide (FACS buffer) for 1 h at 4uC in
the dark. Cells were then washed twice with FACS buffer and
resuspended in 500 ml of FACS buffer. Flow cytometry was
performed on a FACSort (Becton Dickinson, San Jose, CA) with
CellQuest (Becton Dickinson) data acquisition and analysis
software. Nonspecific staining was controlled by isotype matched
antibodies.
Cell cycle analysis: Cells were resuspended in 200 ml 7-AAD
binding buffer (BD Pharmingen). 1.8 ml of ice-cold 70% ethanol
were added drop-wise while vortexing, incubated on ice, spun
down and resuspended in 150 ml binding buffer. 5 ml of 7-AAD
(BD Pharmingen) were added and the cells were left for 15 min in
the dark at RT. The volume was adjusted to 400 ml before flow
cytometry. Data analysis was performed using the software
ModFit.
Death and apoptosis assays
Live and dead cell counts were performed with a haemocy-
tometer after staining with Trypan Blue (Sigma-Aldrich, USA).
Apoptotic and necrotic cells were stained by 10 mg/ml Ethidium
Bromide and 3 mg/ml Acridine Orange, and viewed under the
IX81 microscope (Olympus, USA). Annexin V externalisation was
detected using the Annexin-V Apoptosis Detection Kit (BD
Pharmingen, USA), and analyzed by flow cytometry (CyAnTM,
DakoCytomation, Denmark) and Summit software. Caspase 3
activity was measured using the Caspase 3 Colorimetric Assay Kit
[CPP32], (Chemicon).
Detection of mitochondrial transmembrane potential
3, 39 dihexyloxacarbocyanine iodide (DiOC6), (Invitrogen, San
Diego, USA) was used to measure the mitochondrial transmem-
brane potential Dym. 10
5 cells were cultured for 24 h at 37uC in
12-well plates that had been coated with Fc or CD137-Fc protein.
Cells were loaded with 50 nM of DIOC6 for 30 min in the dark at
37uC. As a positive control, cells were treated with 100 mm H2O2
for 4 h and then loaded with DIOC6. The cells were then
harvested, washed and resuspened in 1X PBS and analyzed
immediately by flow cytometry as described.
Proliferation assays
Cells were pulsed with 0.5 mCi of 3H-thymidine (PerkinElmer,
Boston, MA, USA) for the last 24 h of the culture period. The cells
were then harvested onto a Packard Unifilter Plate using a
MicroMate 196 Cell Harvester and counted using a TopCount
(Perkin Elmer, Waltham, MA, USA).
ELISA
Cytokine concentrations in cell supernatants were determined
by human DuoSet ELISA Development kits (R&D Systems,
Minneapolis, MN, USA), according to the manufacturer’s
instructions. All measurements were performed in triplicate.
Preparation of cell lysates
1.26107 cells were starved of serum, treated under the indicated
conditions and collected for cell lysis to obtain protein samples.
Cells were lysed with EBC lysis buffer (1 M Tris-HCL pH 8.0,
1.5 M NaCl, NP-40, 0.5 M NaF, 100 mM Na3VO4, 250 mg/ml
PMSF, dH20) (Roche Diagnostics, GmbH, Mannheim, Germany).
Complete Mini Protease Inhibitor Cocktail Tablets, (Sigma
Aldrich, St. Louis, MO, USA) and Phosphatase Inhibitor
Cocktails 1 and 2 (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) were added to prevent protein digestion and dephosphor-
ylation, respectively. Cell lysates were then spun at 14,000 rpm for
CD137L in Multiple Myeloma
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10 min to obtain supernatants. Protein samples were stored at
280uC when not used. Protein concentrations were determined
using the Bio-Rad Bradford assay (Bio-Rad Laboratories,
Hercules, CA, USA).
Immunblotting
Protein samples were resolved with 10% SDS Polyacrylamide
gel. 80 mg of protein sample were loaded in each well with 4x
sample buffer. Protein samples were then resolved by electropho-
resis (120 V two hours). The resolved proteins were next
transferred from the polyacrylamide gel to Millipore Immobilon-
PSQ Transfer PVDF membranes (Millipore, Billerica, MA, USA)
using the Bio-Rad SD Semi-dry Transfer system (5 V overnight at
4uC). Membranes were then blocked with a solution of 5% non-fat
milk, 1% Tween 20 in Tris Buffered Saline. Next, the membranes
were incubated with various primary antibodies (Cell Signaling
Technology, Inc, Beverly, MA, USA) at 4uC overnight, washed
and detected using HRP-conjugated secondary antibodies and
Thermo Pierce (Rockford, IL, USA) SuperSignalH West Pico
Chemiluminescent Substrates. Images of the western blots were
visualized and recorded using the Alpha-Innotech FluorChemH
(Alpha Innotech, San Leandro, CA, USA) system.
RNA extraction
Total RNA was extracted from 106 cultured cells with the
appropriate conditions using Rneasy Mini Kit (QIAGEN,
Valencia, CA), according to manufacturer’s manual. Concentra-
tion and purity of the RNA extracted was determined by
spectrophotometry using a 1:10 diluted sample.
Real time reverse transcription PCR
Gene sequences for IL-6 and IkBa were obtained from
GeneBank. Primers for target gene sequences were designed using
Roche Universal Probe Library Assay Design Centre (http://
www.universalprobelibrary.com). The primers used were as
follows: IL-6: 59 – cag gag ccc agc tat gaa ct – 39 (forward) and
59 – agc agg caa cac cag gag – 39 (reverse), for IkBa: 59 – gac gag
gag tac gag cag atg – 39 (forward) and 59 – atg gcc aag tgc agg aac
– 39 (reverse) and GAPDH: 59 – gag tcc act ggc gtc ttc ac – 39
(forward) and 39 – ttc aca ccc atg acg aac at – 39 (reverse). One step
Real Time Reverse Transcription PCR (RT-PCR) was performed
using Roche LightCyclerH system (Roche Diagnostics, GmbH,
Mannheim, Germany). A calibrator control and GAPDH control
were included in every analysis for comparison. The relative fold
change for each gene was calculated using 22DDCT method. The
DDCT formula used for establishing fold change is as follows:
DDCT = (Cp target gene – Cp GAPDH) – (Cp target gene – Cp control).
Nuclear extraction
Nuclear proteins were extracted and isolated from multiple
myeloma cells using the Thermo Scientific NE-PERH Nuclear and
Cytoplasmic Extraction Kit protocol. The cells were lysed in
cytoplasm extraction reagent and spun at 14,000 g to extract the
nuclear material. Proteins from the nuclear material were then
extracted by adding nuclear extraction reagent to the nuclei and
spun at 14,000 g. Nuclear extracts were stored at 280uC until
used. Protein concentrations of the nuclear extracts were measured
using Bio-Rad Bradford protein quantification assay.
NF-kB family transcription factor colorimetric assay
The levels of NF-kB transcription factors (p50, p65, p52 and
RelB) present in the nuclei of treated cells were detected using the
Active Motif (Carlsbad, CA, USA) TransAMTM NF-kB Family
Transcription Factor Assay Kit. Absorbance of individual wells
were measured at 450 nm for 0.1 seconds using the Victor3TM
spectrophotomer (Perkin Elmer, Waltham, MA).
Statistics
Statistical significance was determined using a two-tailed
Student’s t-test.
Results
B cell lymphoma cells express CD137 ligand but not of
CD137
The constitutive expression of CD137 ligand by primary B cells
provides the molecular basis for B cells to receive costimulatory
signals from CD137 [26,27]. Therefore, as a first step in
investigating the effects of CD137 on B cell lymphoma cell lines
we tested CD137 ligand expression. For our studies we selected the
Burkitt’s lymphoma Raji, the non Hodgkin lymphoma SUDHL-4,
the B cell lymphoma DOHH-2 and the three multiple myeloma
(MM) lines SGH-MM5, SGH-MM6 and RPMI 8226. All six cell
lines express CD137 ligand constitutively, but none expresses
CD137, a situation identical to that of primary B cells (Figure 1).
CD137 inhibits proliferation of MM cells
Since CD137 ligand crosslinking enhances proliferation of
preactivated B cells, we tested this activity in B cell lines [22,28].
CD137 ligand stimulation had no significant effect on the
proliferation of the Raji, DOHH-2 and SUDHL-4 cells over
three days as assessed by 3H-thymidine incorporation (Figure 2A).
In contrast, proliferation of the three MM cell lines SGH-MM5,
SGH-MM6 and RPMI 8226 was profoundly decreased by
CD137. This inhibitory effect was most visible at the later time
point of 72 h (Figure 2A). Titration of the CD137-Fc protein
revealed that inhibition of proliferation was of comparable
magnitude between 2.5 and 20 mg/ml, indicating that at 10 mg/
ml CD137 protein is already at its saturation point.
CD137 induces cell death in the MM cell lines by
apoptosis
In order to investigate the mechanism behind the inhibition of
proliferation, we asked next whether CD137 ligand ligation on
MM cells arrested cell cycle progression or induced cell death. The
percentage of dead cells was increased up to 2 to 3-fold in MM
cells after 6 or 24 hours of culture on CD137-Fc compared to Fc
protein (Figure 2B). Viability of the non-MM B cell lymphoma
(non-MM) cell lines was not affected by CD137 ligand signaling.
Cell cycle analysis using 7-AAD staining on SHG-MM5 and
SGH-MM6 cell confirmed induction of MM cell death by CD137
ligand signaling as evidenced by the increase in hypodiploid DNA
(sub-G1/debris peak), (Figure 2C). There was also a decrease in
the number of cells in the S phase, indicating that in addition to
induction of apoptosis cell cycle arrest also contributes to the
inhibitory effect of CD137 ligand signaling.
We next asked whether this reduction in viability was due to
CD137-Fc induced MM cell apoptosis. Annexin-V and 7-AAD
staining revealed increases in the percentages of early (Annexin
V+, 7-AAD2) and late (Annexin V+, 7-AAD+) apoptotic cells at
24 hours (Figure 3A). Consistent with the results from the
proliferation and viability assays (Figure 2), apoptosis rates of
non-MM cell lines were not affected. Induction of apoptosis was
further confirmed by ethidium bromide and acridine orange
staining which showed extensive chromatin condensation and
membrane blebbing after treatment with CD137-Fc (Figure 3B,C)
CD137L in Multiple Myeloma
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and by activation of caspase 3 (Figure 3D). Thus, CD137 reverse
signaling results in an arrest of proliferation as well as an induction
of apoptosis in MM cells while it has no effect on either parameter
in non MM cell lines.
Requirement of immobilisation of CD137 ligand agonists
Many TNF receptor family members such as CD95 require
trimerization and higher order multimerization to initiate
signaling [29]. We observed that cross-linking of CD137 ligand
was essential for induction of cell death and for the reduction of
live cell numbers since addition of recombinant CD137-Fc protein
in a soluble form had no effect (Figure 4A). Also, numbers of live
and apoptotic cells were not different between uncoated wells
(PBS) and Fc protein-coated wells demonstrating no influence of
the Fc control protein (Figure 4B). In the experiments above,
recombinant CD137 protein was used to crosslink CD137 ligand
on MM cells. Anti-CD137 ligand antibodies which can also
crosslink CD137 ligand had the same functional effects on MM
cell lines. The two monoclonal anti-CD137 ligand antibodies,
clones 5F4 and C65-485, induced cell death (Figure 4C), and
cytokine secretion (Figure 4D) in MM cells to a similar extent as
the recombinant CD137-Fc protein. Thus, similar to forward
signaling through receptors of the TNF receptor family, reverse
signaling through CD137 ligand also requires oligomerization
which is consistent with previous studies [24].
Engagement of MM cells via CD137 results in the
expression pro-inflammatory cytokines
Cytokines crucially influence proliferation, survival and death of
healthy and malignant B cell lymphoma cells as well as MM cells.
In particular, IL-6 and IL-8 are important growth and survival
factors for MM cells. The production of IL-6 and IL-8 is enhanced
upon interaction of MM cells with bone marrow stromal cells, and
is dependent on NF-kB activation [30–32]. VEGF (also highly
dependent on NF-kB activity) is crucial in regulating angiogenesis,
while transforming growth factor (TGF)-b is often secreted by
tumor cells to blunt an anti-tumor immune response, or to
increase the cells’ threshold for apoptosis induction [33,34]. In
order to understand what soluble factors may be responsible for
the observed differences to CD137 ligand signaling between the B
cells and MM cells, we next investigated which cytokines if any
were expressed.
Surprisingly, CD137 ligand agonists induced a strong expres-
sion of both IL-6 and IL-8 after 24, 48 or 96 hours that was not
observed in the non-MM cell lines (Figure 5A and B). With the
exception of IL-8 in RPMI 8226 cells, levels of these two cytokines
were either below the detection limit or produced in negligible
amounts in the control unstimulated conditions. VEGF secretion
was enhanced moderately in both MM and non-MM cell lines by
CD137-Fc (Figure 5C), whereas levels of TGF-b were not affected
(not shown). Thus, like normal B cells, MM B cells respond by
producing pro-inflammatory/pro-survival cytokines despite the
observed induction of apoptosis and arrest of growth in MM cells.
Survival signals do not prevent CD137-induced apoptosis
of MM cells
It was surprising to discover that CD137-induced secretion of
IL-6, a potent survival factor for MM cells, given its simultaneous
suppression of proliferation and induction of apoptosis in MM cell
lines. Therefore, we tested whether IL-6 interferes with CD137
ligand-induced cell death. We also included IL-2, the classical
lymphocyte growth and survival factor. Apoptosis was induced in
MM cells by immobilized CD137-Fc protein in the presence of IL-
6 or IL-2. Neither cytokine could rescue MM cells from CD137-
induced apoptosis (Figure 6). In addition, blocking the IL-6
receptor by neutralizing antibodies had no effect on CD137-
induced apoptosis in MM cells (data not shown). Thus, the pro-
apoptotic and growth arrest properties of CD137 reverse signaling
appear to be stronger than the survival response via the production
of IL-6, IL-8 and VEGF.
CD137-induced apoptosis of MM cells occurs through
activation induced cell death
Reverse signaling through CD137 ligand appears to result in
two opposing actions, initiation of pro-survival and/or pro-
inflammatory pathways and initiation of apoptosis and growth
arrest. In order to explain these seemingly contradicting results we
investigated signaling pathways that might explain both phenom-
ena. Consecutive induction of cellular activation and cell death is a
well known phenomenon in leukocytes and termed activation
induced cell death (AICD) [35]. To verify cellular activation in
MM cells that could explain the production of the pro-survival
cytokines, we tested whether CD137 ligand signaling induces the
NF-kB pathway. CD137 stimulation of all three MM cell lines
resulted in a reduction of the levels of the inhibitor of NF-kB
(IkBa) as well as the phosphorylation of the inhibitor at 60 minutes
(Figure 7A). Furthermore, the phosphorylation of p65 (a classical
NF- kB transcription factor) was induced in all three cells lines one
hour after stimulation by CD137 protein. Phosphorylation of p65
resulted in its nuclear translocation in all three cell lines
(Figure 7B). There was no change in the levels of activated p50
as its constitutive levels were already very high (Figure 7B).
However, the activity of NF-kB is determined primarily by the p65
subunit because this rate-limiting subunit contains the transcrip-
tion activation domain [36]. Thus, CD137 ligand signaling
resulted in an early induction of the classical NF-kB transcription
factor in MM cells in a time period consistent with activation that
leads to apoptosis and cytokine production. CD137 induced NF-
kB signaling was functional since it led to the increase in the
transcription of classical NF-kB-regulated gene products such as
IkBa and IL-6 as determined by real-time quantitative RT-PCR
(Figure 7C). Thus, this data indicates that CD137 stimulation of
MM cells results in a potent and early activation of the classical
NF-kB pathway.
AICD in T cells is induced by T cell receptor stimulation, and
relies on CD95/CD95 ligand interaction. AICD can be induced in
different types of B cells through B cell receptor signaling, and this
death induction increases expression of bax, suggesting an
involvement of the intrinsic pathway [37] [38]. In addition, AICD
induced through B cell receptor signaling or CD40 signaling is
independent of CD95 ligand [38,39]. Indeed, we could not detect
any CD137-induced changes CD95 or CD95 ligand, nor in the
expression of death receptor (DR)4 and DR5 and TRAIL (not
shown). However, CD137 ligand signaling led to mitochondrial
membrane depolarization, a characteristic and essential event for
apoptosis mediated by the intrinsic pathway [40]. Mitochondrial
membrane integrity was assessed by staining with DiOC6 whose
mean flourescence intensity was reduced by CD137 ligand
signaling from 131.1 to 70.5 in SGH-MM5 cells, and from 89.4
Figure 1. CD137 ligand is expressed by B cell lymphoma and myeloma cell lines. Cells were stained by PE-conjugated monoclonal
antibodies against CD137 (clone 4B4-1), or anti-CD137 ligand (clone 4B1-436), (open curves) or their isotype control (MOPC-21), (filled curve).
doi:10.1371/journal.pone.0010845.g001
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Figure 2. CD137 inhibits proliferation and induces cell death of MM but not of non-MM cells. Cells were cultured on plate-bound Fc or
CD137-Fc protein or on uncoated plates (PBS). (A) After indicated times proliferation was determined via 3H-thymidine incorporation. (B) Cell viability
was determined after 24, 48, 72 and 96 h via trypan blue staining. Depicted are means 6 standard deviations of triplicate measurements. * p,0.05.
This experiment is representative of three independent experiments with similar results.
doi:10.1371/journal.pone.0010845.g002
CD137L in Multiple Myeloma
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to 51.2 in SGH-MM6 cells (Figure 7D). This data suggests that the
apoptosis induced by CD137 ligand signals initiate intrinsic
apoptotsis pathways.
Discussion
In this study we identified unexpected activities of CD137
ligand crosslinking on MM cell lines. CD137 ligand signaling
inhibited proliferation, induced cell cycle arrest and apoptosis and
resulted in an increased secretion of IL-6 and IL-8 selectively in
MM cell lines but not in non-MM B cell lymphoma cells. These
data were unexpected as CD137 is known to enhance activation
and proliferation of primary B cells [22,28]. We had hypothesized
that CD137 would also enhance proliferation of B cell lines,
especially since CD137 can be expressed as a neoantigen by
certain B cell lymphomas (our unpublished data). In theory, the
ectopic expression of CD137 could enable malignant B cells to
send and receive growth signals in an auto- or paracrine manner
which under physiological conditions are delivered by CD137-
expressing helper T cells or follicular dendritic cells [22,23].
Figure 3. CD137 induces apoptosis in the MM cell lines. (A) SGH-MM5 cells at a density of 106 cells/ml were cultured on plate-bound Fc or
CD137-Fc protein or on uncoated plates (PBS). After 24 h the cells were stained with Annexin V and 7-AAD. Similar results were obtained for the other
MM cell lines. (B) Cells from (A) were stained with Acridine Orange (green) and Ethidium Bromide (red). Photographs were taken at a magnification of
406. (C) CD137-Fc treated SGH-MM5 cells of B at a magnification of 2006. (D) Caspase 3 activity was determined 6 h after exposure of SGH-MM5 and
RPMI 8226 cells to immobilized Fc or CD137-Fc protein. These experiments are representative of three independent experiments with similar results.
doi:10.1371/journal.pone.0010845.g003
CD137L in Multiple Myeloma
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CD137 ligand signals induced secretion of IL-6 and IL-8
specifically in the MM cell lines but not the non MM B cell
lymphoma lines. IL-6 has been shown to be essential for MM growth
and for protection from apoptosis [31,32], and increased IL-6 levels
in MM patient sera correlate with disease progression [33,41].
Similarly, IL-8 supports MM growth, and IL-8 secretion by bone
marrow stromal also correlates with MM progression [30]. VEGF is
also induced by CD137 ligand signals although to a lower extent, and
in both MM and non-MM cell lines. VEGF is a potent growth factor
for MM cells, and supports MM growth by inducing angiogenesis
[42,43]. All of these cytokines are strongly induced at the
transcriptional level by the classical NF-kB pathways that rely on
the activation of transcription factors, p65/p50.
It is at first sight surprising that a cellular signal can induce both
cell death and cell activation at the same time. NF-kB activation
and secretion of pro-survival cytokines clearly indicate a role for
cellular activation by CD137 ligand signaling. Induction of
apoptosis could be a result of AICD. AICD is a well known
phenomenon in activated lymphocytes [35]. The finding that
CD137 ligand agonist-induced apoptosis is not inhibited by
addition of IL-6 or IL-2 also supports AICD as a potential
mechanism of CD137 ligand-induced apoptosis.
CD40 shares many similarities with CD137, and indeed anti-
CD40 antibodies have a direct cytotoxic effect in various B cell
malignancies including MM [44,45]. Phase I clinical trials with
CD40 agonists are being conducted on MM patients with
encouraging results [46]. Although the exact mechanism of anti-
CD40 induced B cell death is not known, the most plausible
mechanism is one that relies on AICD [47,48]. However, CD40 is
also known to exert proliferative effects as well. For example,
soluble CD40 ligand is sufficient to induce proliferation of MM
cells whereas normal B cells require both CD40 ligand and IL-4
for full activation [25], suggesting that CD40 ligand act differently
on different cells, and that MM cells exist at a stage of
differentiation or activation that does not require a second signal
such as IL-4. Finally, CD40 stimulation has been shown to induce
apoptosis or proliferation in different cell types despite the
activation of the NF-kB pathway in both instances [46]. Thus,
Figure 4. Requirement of immobilization of CD137 ligand agonists. SGH-MM5 (A and B) or SGH-MM6 (C and D) cells at a density of 106 cells/
ml were cultured on uncoated plates (PBS), or on plate-bound Fc, CD137-Fc, mouse IgG (MOPC21) or anti-CD137 ligand antibody (clones 5F4 and
C65-485) or on uncoated plates (PBS), or to which Fc or CD137-Fc proteins were added soluble at 10 mg/ml. (A) Percentage of dead cells (left panel)
and number of total live cells (right panel) were determined after 24 h via trypan blue staining. (B) Extent of apoptosis of cells in (A) was determined
by Annexin V and 7-AAD staining. (C) Percentages of dead cells were determined at indicated times via trypan blue staining. (D) IL-8 concentrations in
24 h cell supernatants as determined by ELISA. Depicted are means 6 standard deviations of triplicate measurements. * p,0.05.
doi:10.1371/journal.pone.0010845.g004
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Figure 5. CD137 ligand signaling results in upregulation of pro-inflammatory cytokines in MM but not in non-MM cell lines. Cells at a
density of 106 cells/ml were cultured on plate-bound Fc (white bars) or CD137-Fc protein (black bars). (A) IL-6, (B) IL-8 and (C) VEGF concentrations in
24, 48 and 72 h cell supernatants were determined by ELISA. Depicted are means 6 standard deviations. * p,0.05. This experiment was performed
three times with similar results.
doi:10.1371/journal.pone.0010845.g005
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just as CD40 signaling results in proliferation in some cells and
apoptosis in others, CD137 ligand signaling may have similar
diverse effects depending on the cell type.
Non-MM cell lines expressed similar levels of CD137 ligand as
the MM cell lines. And crosslinking of CD137 ligand enhanced
VEGF secretion in non-MM cell lines demonstrating that CD137
ligand signaling is functional in these cells. However, inhibition of
proliferation, induction of apoptosis and IL-6 and IL-8 secretion
were specific for the MM cell lines. The molecular basis of this
difference in biological responses between MM and non-MM cell
lines is not known but is currently being addressed by ongoing
research. One possible explanation could be provided by the
recent finding that many MM tumors have constitutively activated
NF-kB [49,50]. Therefore, any additional stimulation such as by
CD137 or by anti-CD40 antibodies may induce AICD in MM
cells. It will be interesting to determine the exact intracellular
mechanisms of the proposed AICD and compare the components
of that system between B lymphoma and MM cells.
An important question arising from this data is whether CD137
ligand agonists can also induce death of malignant plasma cells
from MM patients. If that proves to be the case a recombinant
CD137 protein or anti-CD137 ligand antibodies could be
evaluated for MM therapy. It would be especially important to
Figure 6. CD137-induced MM cell death is not inhibited by IL-6
or IL-2. SGH-MM6 cells at a density of 1.26106 cells/ml were cultured
on plate-bound Fc or CD137-Fc protein or on uncoated plates (PBS),
and IL-6 (1 ng/ml) or IL-2 (100 units/ml) were added. Cell viability was
determined after 24 h via trypan blue staining. Depicted are means 6
standard deviations of percentages live cells from triplicate measure-
ments. * p,0.05. This experiment is representative of three indepen-
dent experiments with similar results.
doi:10.1371/journal.pone.0010845.g006
Figure 7. Early activation of the classical NF-kB pathway is initiated upon CD137 ligand signaling. SGH-MM5, SGH-MM6 and RPMI 8226
cells were treated with plate-bound Fc or CD137-Fc. (A) Total protein was extracted at indicated times. NF-kB signaling proteins were detected by
immunoblotting. (B) Cells were treated with CD137-Fc for indicated times and nuclear extracts were isolated and subjected to NF-kB transcription
factor assay analysis. Data is represented by the average of triplicates within the experiment and is representative of two independent experiments. P
values were calculated using pair wise t-test comparing time zero to time 60 min. * p,0.05. (C) Cells were treated with plate bound Fc or CD137-Fc
protein for six hours following which total RNA was extracted. Real time RT-PCR was performed on both human IkBa and IL-6 transcripts. RT-PCR data
is represented by fold change as calculated using the 2DDCT method where GADPH served as a reference gene, and where each data point was
performed in triplicate. (D) Cells were cultured for 48 h on plates with immobilized Fc (white open curve) or CD137-Fc protein (grey filled curve), and
then stained with 50 nM DiOC6 and analyzed by flow cytometry. Cells with no DiOC6 added were used as background control (hatched).
doi:10.1371/journal.pone.0010845.g007
CD137L in Multiple Myeloma
PLoS ONE | www.plosone.org 10 May 2010 | Volume 5 | Issue 5 | e10845
assess whether CD137 ligand agonists amplify the therapeutic
effects and synergize with current MM therapies such as
dexamethasone, thalidomide or proteasome inhibitors.
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